Effectiveness and safety of bulevirtide monotherapy 2 mg/die in hdv patients with compensated cirrhosis and clinically significant portal hypertension
Digestive and Liver Disease(2022)
摘要
Introduction: Bulevirtide (BLV) has been recently approved for the treatment of HDV-related chronic hepatitis or compensated cirrhosis in Europe, but its effectiveness and safety in patients with advanced cirrhosis and severe portal hypertension are still unknown.
更多查看译文
关键词
bulevirtide monotherapy,hdv patients,cirrhosis,hypertension
AI 理解论文
溯源树
样例
![](https://originalfileserver.aminer.cn/sys/aminer/pubs/mrt_preview.jpeg)
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要